Journal: Plants

Article Title: Screening for Selective Anticancer Activity of 65 Extracts of Plants Collected in Western Andalusia, Spain

doi: 10.3390/plants10102193

Figure Lengend Snippet: Cytotoxic activity of Tetraclinis articulata (Vahl) Mast. ( 58 ) against 14 cancer cell lines from a variety of tissues.

Article Snippet: HNO97 (human tongue cancer cells), A64-CLS (human submaxillary gland adenoma cells), AN3Ca (human endometrial adenocarcinoma cells), Sk-OV-3 (human ovarian cancer cells), KATO III (human gastric cancer cells), Sk-Br-3 (HER2-positive breast cancer cells), T24 (human bladder cancer cells), Calu-1 (human squamous lung cancer cells), and MeWo (human BRAF wild-type melanoma cells) were purchased from Cell Lines Service (CLS).

Techniques: Activity Assay

Journal: The Journal of Clinical Investigation

Article Title: Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma

doi: 10.1172/JCI91291

Figure Lengend Snippet: (A) Western blot analysis of FES in MeWo cell line with overexpression of FES. Actin served as a loading control. (B) Clonogenic assay of MeWo cells with and without expression of exogenous FES. Error bars indicate mean ± SEM (n = 4 biological replicates per group). (C) Soft agar assay of MeWo cells with and without expression of exogenous FES. Error bars indicate mean ± SEM (n = 3 biological replicates per group). (D) Mice (n = 9) were injected with 1 × 106 MeWo cells to the left or MeWo cells expressing exogenous FES to the right side of the body. The tumor volume was measured every 3 to 4 days up to day 24. Error bars indicate mean ± SEM (n = 9 biological replicates per group). (E) Schematic indicating the location of the FES kinase-dead mutation. F-B, F-BAR domain. (F) Western blot analysis of doxycycline-induced expression of WT or mutant FES in MeWo cell line. Vinculin served as a loading control. (G) Clonogenic assay of MeWo cells expressing WT or mutant FES. Quantification of the assay measured as the percentage of area covered is shown in the graph on the right. Error bars indicate mean ± SEM (n = 3 biological replicates per group). Statistical significance was determined by unpaired 2-sided t test (B, G) and 2-way ANOVA (C, D).

Article Snippet: MeWo cells (1 million) were injected in 150 μl of 0.9% NaCl subcutaneously into nude mice (Janvier).

Techniques: Western Blot, Over Expression, Control, Clonogenic Assay, Expressing, Soft Agar Assay, Injection, Mutagenesis

Journal: International Journal of Molecular Sciences

Article Title: Human Microfibrillar-Associated Protein 4 (MFAP4) Gene Promoter: A TATA-Less Promoter That Is Regulated by Retinol and Coenzyme Q10 in Human Fibroblast Cells

doi: 10.3390/ijms21218392

Figure Lengend Snippet: The expression of pEGFP- pMFAP4 plasmids in mouse fibroblast NIH/3T3 cells, human melanoma MeWo cells, and mouse melanoma B16-F10 cells. ( A ) Fluorescence images. Scale bar = 100 μm. ( B ) Relative fluorescence intensity. Data are presented as means ± SE.

Article Snippet: Detroit 551 cells (BCRC 60118, human normal fibroblast cells), MeWo cells (BCRC 60540, human melanoma cells), NIH/3T3 cells (BCRC 60008, mouse fibroblast cells), and B16-F10 cells (BCRC 60031, mouse melanoma cells) were all obtained from the Bioresource Collection and Research Center (BCRC, Hsinchu, Taiwan, ROC).

Techniques: Expressing, Fluorescence

Journal: British Journal of Cancer

Article Title: Clinically proven markers of metastasis predict metastatic spread of human melanoma cells engrafted in scid mice

doi: 10.1038/sj.bjc.6603594

Figure Lengend Snippet: (a) Characteristics of six human melanoma cell lines xenografted into scid mice ( n =10 per cell line) and (b) glycoconjugate expression of their respective primary tumours and spontaneous lung metastasis

Article Snippet: The human melanoma cell lines UISO-Mel6 (established from a primary malignant melanoma; see Rauth et al (1998) ), MV3 (established from a metastatic melanoma lymph node; see ) and MeWo (established from a metastatic melanoma lymph node of a white, 78-year-old male; see Carey et al (1976) ) were kindly provided by the Klinik für Dermatologie, Universitätsklinikum Hamburg-Eppendorf, Germany.

Techniques: Mouse Assay, Expressing

Journal: British Journal of Cancer

Article Title: Clinically proven markers of metastasis predict metastatic spread of human melanoma cells engrafted in scid mice

doi: 10.1038/sj.bjc.6603594

Figure Lengend Snippet: Correlation of tumour weight and number of lung metastasis of human melanoma cell lines subcutaneously xenografted into scid mice

Article Snippet: The human melanoma cell lines UISO-Mel6 (established from a primary malignant melanoma; see Rauth et al (1998) ), MV3 (established from a metastatic melanoma lymph node; see ) and MeWo (established from a metastatic melanoma lymph node of a white, 78-year-old male; see Carey et al (1976) ) were kindly provided by the Klinik für Dermatologie, Universitätsklinikum Hamburg-Eppendorf, Germany.

Techniques:

Journal: British Journal of Cancer

Article Title: Clinically proven markers of metastasis predict metastatic spread of human melanoma cells engrafted in scid mice

doi: 10.1038/sj.bjc.6603594

Figure Lengend Snippet: Comparative analysis of glycoconjugate expression of six human melanoma cell lines in vitro (a) and in vivo (b)

Article Snippet: The human melanoma cell lines UISO-Mel6 (established from a primary malignant melanoma; see Rauth et al (1998) ), MV3 (established from a metastatic melanoma lymph node; see ) and MeWo (established from a metastatic melanoma lymph node of a white, 78-year-old male; see Carey et al (1976) ) were kindly provided by the Klinik für Dermatologie, Universitätsklinikum Hamburg-Eppendorf, Germany.

Techniques: Expressing, In Vitro, In Vivo

Journal: Journal for Immunotherapy of Cancer

Article Title: Oncolytic varicella-zoster virus engineered with ORF8 deletion and armed with drug-controllable interleukin-12

doi: 10.1136/jitc-2023-008307

Figure Lengend Snippet: VZV vOka vaccine strain demonstrates potent antitumor activity in human melanoma xenograft model. (A) Schematic of experimental design. Human MeWo melanoma cells were implanted subcutaneously on day 0. Viruses were IT delivered on days 14, 16, and 18 (5×10 4 PFUs per injection). (B) Blood bHCG levels. Blood samples were collected on day 5 post-treatment, and plasma bHCG levels were compared between treatment groups (n=4, unpaired t-test). (C) Tumor growth curves (n=10, two-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test). (D) Animal survival curves (n=10, Log-rank (Mantel-Cox) test). ns, not significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. bHCG, beta-human chorionic gonadotropin; IT, intratumorally; PFU, plaque-forming unit; VZV, varicella-zoster virus.

Article Snippet: For the human MeWo melanoma immune-comprised tumor model, MeWo cells suspended in PBS (5×10 7 cells/mL) were subcutaneously implanted to the right flanks (100 μL per mouse) of 6 weeks old female nude mice (NCRNU-F, Taconic).

Techniques: Activity Assay, Injection, Clinical Proteomics, Virus

Journal: Journal for Immunotherapy of Cancer

Article Title: Oncolytic varicella-zoster virus engineered with ORF8 deletion and armed with drug-controllable interleukin-12

doi: 10.1136/jitc-2023-008307

Figure Lengend Snippet: Deletion of ORF8 attenuates VZV replication while not reducing virus antitumor potency. (A) Construction of VZV Ellen-BAC-ΔORF8 and Ellen-BAC-ΔORF65. (B) Growth curves of Ellen-ΔORF8 and Ellen-ΔORF65. The ARPE-19 cells, dSH-SY5Y neuronal cells, or MeWo cells cultured in six-well plates were infected with viruses on day 0 (1000 PFUs per well), and virus titers on days 3, 6, and 9 were detected (n=3). Virus growth curves were compared between the wild-type backbone virus and mutant viruses (two-way analysis of variance (ANOVA) with Dunnett’s multiple comparisons test (for ARPE-19 cells and MeWo cells) or Tukey’s multiple comparisons test (for dSH-SY5Y cells)). (C) Schematic of experimental design. Human MeWo melanoma cells were implanted subcutaneously on day 0 (n=8). Viruses were IT delivered on days 20, 22, and 24 (5×10 4 PFUs per injection). (D) Intratumoral virus replication. Tumor slices from different therapy groups (collected on day 5 post-treatment) were stained with anti-VZV ORF68 (gE) antibody (Alexa Flour 594). Representative images were displayed. Scale bars=100 µm. (E) Efficacy of VZV Ellen-ΔORF8 and Ellen-ΔORF65. Tumor growth curves were displayed, and animal survival curves were compared with the Gehan-Breslow-Wilcoxon test. ns, not significant, *p<0.05, **p<0.01, ***p<0.001. BAC, bacterial artificial chromosome; IT, intratumorally; PFU, plaque-forming unit; VZV, varicella-zoster virus.

Article Snippet: For the human MeWo melanoma immune-comprised tumor model, MeWo cells suspended in PBS (5×10 7 cells/mL) were subcutaneously implanted to the right flanks (100 μL per mouse) of 6 weeks old female nude mice (NCRNU-F, Taconic).

Techniques: Virus, Cell Culture, Infection, Mutagenesis, Injection, Staining

Journal: Journal for Immunotherapy of Cancer

Article Title: Oncolytic varicella-zoster virus engineered with ORF8 deletion and armed with drug-controllable interleukin-12

doi: 10.1136/jitc-2023-008307

Figure Lengend Snippet: Deletion of ORF8 from VZV improves safety in human MeWo melanoma xenograft model. (A) Insertion of scIL12 into VZV Ellen genome. The elongation factor-1α/ human T-cell leukemia virus (EF1/HTLV) composite promoter-driven scIL12 was inserted between ORF60 and ORF61. (B) In vivo testing of Ellen-scIL12, Ellen-ΔORF8-scIL12, and Ellen-ΔORF65-scIL12. Human MeWo melanoma cells were implanted subcutaneously on day 0 (n=9). Viruses were IT delivered on days 20, 22, and 24 (5×10 4 PFUs per injection). Tumor growth curves were displayed. (C) Blood IL12 concentration. Plasma samples were collected on day 5 post-treatment, and IL12 p70 concentrations were determined by ELISA and compared with one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test. (D) Deletion of ORF8 led to a decrease in treatment-related mortality. Treatment or tumor growth-related animal deaths were recorded for each group. ND, not detected. (E) Animal survival curves (Log-rank (Mantel-Cox) test). (F) Average body weight. ns, not significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. IL12, interleukin-12; IT, intratumorally; PFU, plaque-forming unit; scIL12, single-chain IL12; VZV, varicella-zoster virus.

Article Snippet: For the human MeWo melanoma immune-comprised tumor model, MeWo cells suspended in PBS (5×10 7 cells/mL) were subcutaneously implanted to the right flanks (100 μL per mouse) of 6 weeks old female nude mice (NCRNU-F, Taconic).

Techniques: Virus, In Vivo, Injection, Concentration Assay, Clinical Proteomics, Enzyme-linked Immunosorbent Assay

Journal: Journal for Immunotherapy of Cancer

Article Title: Oncolytic varicella-zoster virus engineered with ORF8 deletion and armed with drug-controllable interleukin-12

doi: 10.1136/jitc-2023-008307

Figure Lengend Snippet: VZV armed with drug-controllable scIL12. (A) Insertion of tet-off controllable scIL12 into VZV Ellen genome. The ORF8 coding sequence was replaced by tet-off-scIL12 cassette. tTA, tetracycline transactivator protein. The pTight promoter contains a modified tet response element (TRE). Without doxycycline, the tTA protein binds to TRE and activates the expression of scIL12. The introduction of doxycycline leads to its binding with tTA, thus silencing the transactivation of genes controlled by TRE. (B, C) Drug controllable expression of IL12 in Ellen-ΔORF8-tet-off-scIL12. The MeWo cells were seeded in a 24-well plate (2×10 5 cells/well) on day 0 and were cultured overnight. On day 1, cells were infected with Ellen-ΔORF8-tet-off-scIL12 (200 PFUs per well), and doxycycline was added to the infected cells at different concentrations (0, 1, or 5 µg/mL). IL12 p70 concentration in the supernatant and virus titers on day 4 were detected (n=3). For each virus, IL12 concentrations and virus titers in the wells with or without doxycycline treatment were compared (one-way ANOVA with Tukey’s multiple comparisons test). ns, not significant,****p<0.0001. IL12, interleukin-12; PFU, plaque-forming unit; scIL12, single-chain IL12; VZV, varicella-zoster virus.

Article Snippet: For the human MeWo melanoma immune-comprised tumor model, MeWo cells suspended in PBS (5×10 7 cells/mL) were subcutaneously implanted to the right flanks (100 μL per mouse) of 6 weeks old female nude mice (NCRNU-F, Taconic).

Techniques: Sequencing, Modification, Expressing, Binding Assay, Cell Culture, Infection, Concentration Assay, Virus